Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAET1L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAET1L ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View RAET1L Products |
| Gene Delivery | RAET1L Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-surface conformation assays. |
View RAET1L Products |
| Benchmark Ab | Anti-RAET1L Recombinant Antibody Recombinant positive control derived from benchmark clinical sequences. |
View RAET1L Products |
| Validator | RAET1L siRNA Set For target knockdown verification in functional NK-cell co-culture assays. |
View RAET1L Products |
| Related Target A | NKG2D (KLRK1) The primary activating receptor for RAET1L on NK cells and CD8+ T cells. Crucial for receptor-ligand interaction assays. |
View NKG2D Products |
| Related Target B | MICA Parallel NKG2D ligand. Essential for selectivity screening and off-target cross-reactivity profiling. |
View MICA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding-resistant ligand screening | HEK293 expressed recombinant RAET1L extracellular domain (ECD) preserving native post-translational modifications. |
| NKG2D subfamily cross-reactivity | Complete panel of human NKG2D ligands (MICA, MICB, ULBP1-6) with sequence-verified purity >95%. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RAET1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the NKG2D-ligand axis, specifically RAET1L (ULBP6), is rapidly gaining traction in cancer immunotherapy and autoimmune disease management. As one of the highest-affinity ligands for the activating receptor NKG2D, RAET1L plays a pivotal role in modulating natural killer (NK) cell and T-cell mediated cytolysis. The next wave of R&D is focused on overcoming tumor-mediated shedding of RAET1L and utilizing bispecific or trispecific NK-cell engagers (NKCEs) to selectively reactivate the immune response within the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engagers (NKCEs) | Innate Pharma, Sanofi | Hematological Malignancies, Solid Tumors | Multi-specific binding assays (Requires high-purity RAET1L and NKG2D proteins) |
| CAR-NK / CAR-T Cells | Celyad Oncology, Nkarta Therapeutics | Colorectal Cancer, Ovarian Cancer | Target expression validation on target cells (Requires Lentivirus for stable overexpressing lines) |
| Monoclonal Antibodies (mAbs) | Academic Institutes, Biopharma startups | Autoimmune Diseases (e.g., Alopecia Areata) | Blocking/Neutralization assays (Requires sequence-verified RAET1L ECD-Fc) |